Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.

Viral Hepatitis

Quick Links

Veterans Crisis Line Badge
My healthevet badge

Hepatitis C Quicknotes: Rules for Adjusting Therapy for CBC Changes

for Health Care Providers

Antiviral TX Strategy

Rules For Adjusting Therapy According To CBC Changes

  1. Hgb 10-11 g/dL
    • Peginterferon.
      • Do not modify dosage
    • Ribavirin
      • If no or minimal symptoms, do not modify dosage
      • If symptomatic, decrease by 200 mg/day and/or consider erythropoietin, particularly if cirrhotic, posttransplant, or HIV/HCV coinfected
    • Candidates for Recombinant Erythropoietin Criteria for Use for Hepatitis C Treatment-Related Anemia
      • Rule out other causes of anemia
      • Anemia persists at 2 weeks after reducing ribavirin
      • No hypertension
    • Dosage:
      • Epoetin alfa 40,000 units SC/week
      • Darbepoetin alfa 200 mcg SC every other week
    • Goal:
      • Hemoglobin 12 g/dL
  2. Hgb 8.5-10 g/dL
    • Peginterferon
      • Do not modify dosage
    • Ribavirin
    • Candidates for erythropoietin
      • Rule out other causes of anemia
      • Anemia persists at 2 weeks after reducing ribavirin
      • No hypertension
    • Dosage:
      • Epoetin alfa 40,000 units SC weekly
      • Darbepoetin alfa 200 mcg SC every other week
    • Goal:
      • Hemoglobin 12 g/dL
  3. Hgb <8.5 g/dL
    • Peginterferon.
      • Do not modify dosage
    • Ribavirin
      • Discontinue until resolution
  4. WBC <1,500
    • Peginterferon alfa 2b
      • Reduce dosage by 50% and reevaluate
    • Ribavirin
      • Do not modify dosage
  5. WBC <1,000
    • Peginterferon alfa 2b
      • Discontinue until resolution
    • Ribavirin
      • Do not modify dosage
  6. ANC <750
    • Peginterferon
      • Reduce peginterferon alfa 2a dosage to 135 mcg/wekk and reevaluate
      • Reduce peginterferon alfa 2b dosage by 50% and reevaluate
    • Ribavirin
      • Do not modify dosage
  7. ANC <500
    • Peginterferon
      • Discontinue until resolution
    • Ribavirin
      • Do not modify dosage
    • Consider G-CSF in patients who are cirrhotic, posttransplant, or HIV/HCV coinfected, particularly if neutropenia persists despite peginterferon dosage reduction
  8. Platelets <80,000
    • Peginterferon
      • Reduce peginterferon alfa 2b dosage by 50% and reevaluate
    • Ribavirin
      • Do not modify dosage
  9. Platelets <50,000
    • Peginterferon
      • Reduce peginterferon alfa 2a dosage to 90 mcg/week and reevaluate
      • Discontinue peginterferon alfa 2b until resolution
    • Ribavirin
      • Do not modify dosage
  10. Platelets <25,000
    • Peginterferon
      • Discontinue until resolution
    • Ribavirin
      • Do not modify dosage

Next: Endpoints of HCV Therapy